Mayabeque, Cuba: The workers of the National Center for Bio-preparations have more than 50 percent of the filling and review of the vaccine candidate Soberana 02 ready to be used in the clinical trial of the third phase.
At this time, Biocen’s fundamental challenges are ensuring all productive capacity, complying with BioCubaFarma’s organizational strategy, linking scientific centers to make the vaccines that will be used to counteract Covid-19 successfully in a short time.
The Director General of the Scientific Center, Doctor of Science, Tamara Lobaina Rodríguez, recognized the satisfactory results of this connection, both in the west and in the east of the country.
Of the protocols applied for the control of Covid-19, two are the result of technological innovation in Biocen: Biomodulin T and the BTB transport medium for the transfer of samples.
The dynamics imposed by the pandemic caused changes in the ways of doing things and the alliances gained space among Cuban scientific institutions.
From its main mission, this biotechnology industry, belonging to the municipality of Bejucal, enhances its outstanding history, to the pride of Mayans, the member of the Central Committee of the Communist Party of Cuba (PCC) and its first secretary in Mayabeque, Yanina de la Nuez Aclich said.
